Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets

The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glyc...

Full description

Saved in:

Bibliographic Details
Published in:	Adipocyte Vol. 2; no. 4; pp. 266 - 271
Main Authors:	Pejnovic, Nada N, Pantic, Jelena M, Jovanovic, Ivan P, Radosavljevic, Gordana D, Djukic, Aleksandar Lj, Arsenijevic, Nebojsa N, Lukic, Miodrag L
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis 22.10.2013 Informa UK Limited Landes Bioscience
Subjects:	Commentary galectin-3 IL-1β inflammation insulin resistance NFκB NLRP3 inflammasome obesity type 2 diabetes type 2 diabetes NFκB inflammation IL-1β NLRP3 inflammasome galectin-3 insulin resistance obesity
ISSN:	2162-3945, 2162-397X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glycation end products (AGE), modified lipoproteins, and endotoxin. In the recently published study we demonstrate proinflammatory changes in the visceral adipose tissue and pancreatic islets in galectin-3-deficient mice fed high-fat diet which also exhibited excess adiposity, hyperglycemia, insulin resistance and systemic inflammation compared with their diet matched wild-type controls. This was associated with the increased incidence of Type-1 T and NKT cells and pro-inflammatory CD11c + CD11b + macrophages in the visceral adipose tissue. Severe insulitis, infiltration of macrophages expressing NLRP3 inflammasome and IL-1β, and enhanced accumulation of AGE were present within the pancreatic islets in obese LGALS3 −/− mice. Moreover, increased caspase-1 dependent IL-1β secretion with increased expression of NLRP3 inflammasome and phospho-NFκBp65 were observed in LGALS3 −/− peritoneal macrophages stimulated in vitro by lipopolysaccharide and/or saturated fatty acid palmitate. The amplified high-fat diet-induced obesity and hyperglycemia and exacerbated inflammation in adipose tissue and pancreatic islets in LGALS3 −/− mice suggest an important role for galectin-3 in the regulation of adiposity, metaflammation and type 2 diabetes.
AbstractList	The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glycation end products (AGE), modified lipoproteins, and endotoxin. In the recently published study we demonstrate proinflammatory changes in the visceral adipose tissue and pancreatic islets in galectin-3-deficient mice fed high-fat diet which also exhibited excess adiposity, hyperglycemia, insulin resistance and systemic inflammation compared with their diet matched wild-type controls. This was associated with the increased incidence of Type-1 T and NKT cells and pro-inflammatory CD11c+CD11b+ macrophages in the visceral adipose tissue. Severe insulitis, infiltration of macrophages expressing NLRP3 inflammasome and IL-1β, and enhanced accumulation of AGE were present within the pancreatic islets in obese LGALS3−/− mice. Moreover, increased caspase-1 dependent IL-1β secretion with increased expression of NLRP3 inflammasome and phospho-NFκBp65 were observed in LGALS3−/− peritoneal macrophages stimulated in vitro by lipopolysaccharide and/or saturated fatty acid palmitate. The amplified high-fat diet-induced obesity and hyperglycemia and exacerbated inflammation in adipose tissue and pancreatic islets in LGALS3−/− mice suggest an important role for galectin-3 in the regulation of adiposity, metaflammation and type 2 diabetes. The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glycation end products (AGE), modified lipoproteins, and endotoxin. In the recently published study we demonstrate proinflammatory changes in the visceral adipose tissue and pancreatic islets in galectin-3-deficient mice fed high-fat diet which also exhibited excess adiposity, hyperglycemia, insulin resistance and systemic inflammation compared with their diet matched wild-type controls. This was associated with the increased incidence of Type-1 T and NKT cells and pro-inflammatory CD11c(+)CD11b(+) macrophages in the visceral adipose tissue. Severe insulitis, infiltration of macrophages expressing NLRP3 inflammasome and IL-1β, and enhanced accumulation of AGE were present within the pancreatic islets in obese LGALS3(-/-) mice. Moreover, increased caspase-1 dependent IL-1β secretion with increased expression of NLRP3 inflammasome and phospho-NFκBp65 were observed in LGALS3(-/-) peritoneal macrophages stimulated in vitro by lipopolysaccharide and/or saturated fatty acid palmitate. The amplified high-fat diet-induced obesity and hyperglycemia and exacerbated inflammation in adipose tissue and pancreatic islets in LGALS3(-/-) mice suggest an important role for galectin-3 in the regulation of adiposity, metaflammation and type 2 diabetes.The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glycation end products (AGE), modified lipoproteins, and endotoxin. In the recently published study we demonstrate proinflammatory changes in the visceral adipose tissue and pancreatic islets in galectin-3-deficient mice fed high-fat diet which also exhibited excess adiposity, hyperglycemia, insulin resistance and systemic inflammation compared with their diet matched wild-type controls. This was associated with the increased incidence of Type-1 T and NKT cells and pro-inflammatory CD11c(+)CD11b(+) macrophages in the visceral adipose tissue. Severe insulitis, infiltration of macrophages expressing NLRP3 inflammasome and IL-1β, and enhanced accumulation of AGE were present within the pancreatic islets in obese LGALS3(-/-) mice. Moreover, increased caspase-1 dependent IL-1β secretion with increased expression of NLRP3 inflammasome and phospho-NFκBp65 were observed in LGALS3(-/-) peritoneal macrophages stimulated in vitro by lipopolysaccharide and/or saturated fatty acid palmitate. The amplified high-fat diet-induced obesity and hyperglycemia and exacerbated inflammation in adipose tissue and pancreatic islets in LGALS3(-/-) mice suggest an important role for galectin-3 in the regulation of adiposity, metaflammation and type 2 diabetes. The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glycation end products (AGE), modified lipoproteins, and endotoxin. In the recently published study we demonstrate proinflammatory changes in the visceral adipose tissue and pancreatic islets in galectin-3-deficient mice fed high-fat diet which also exhibited excess adiposity, hyperglycemia, insulin resistance and systemic inflammation compared with their diet matched wild-type controls. This was associated with the increased incidence of Type-1 T and NKT cells and pro-inflammatory CD11c(+)CD11b(+) macrophages in the visceral adipose tissue. Severe insulitis, infiltration of macrophages expressing NLRP3 inflammasome and IL-1β, and enhanced accumulation of AGE were present within the pancreatic islets in obese LGALS3(-/-) mice. Moreover, increased caspase-1 dependent IL-1β secretion with increased expression of NLRP3 inflammasome and phospho-NFκBp65 were observed in LGALS3(-/-) peritoneal macrophages stimulated in vitro by lipopolysaccharide and/or saturated fatty acid palmitate. The amplified high-fat diet-induced obesity and hyperglycemia and exacerbated inflammation in adipose tissue and pancreatic islets in LGALS3(-/-) mice suggest an important role for galectin-3 in the regulation of adiposity, metaflammation and type 2 diabetes. The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including type 2 diabetes. Galectin-3, a β-galactoside-binding lectin, modulates immune/inflammatory responses and specifically binds to advanced glycation end products (AGE), modified lipoproteins, and endotoxin. In the recently published study we demonstrate proinflammatory changes in the visceral adipose tissue and pancreatic islets in galectin-3-deficient mice fed high-fat diet which also exhibited excess adiposity, hyperglycemia, insulin resistance and systemic inflammation compared with their diet matched wild-type controls. This was associated with the increased incidence of Type-1 T and NKT cells and pro-inflammatory CD11c + CD11b + macrophages in the visceral adipose tissue. Severe insulitis, infiltration of macrophages expressing NLRP3 inflammasome and IL-1β, and enhanced accumulation of AGE were present within the pancreatic islets in obese LGALS3 −/− mice. Moreover, increased caspase-1 dependent IL-1β secretion with increased expression of NLRP3 inflammasome and phospho-NFκBp65 were observed in LGALS3 −/− peritoneal macrophages stimulated in vitro by lipopolysaccharide and/or saturated fatty acid palmitate. The amplified high-fat diet-induced obesity and hyperglycemia and exacerbated inflammation in adipose tissue and pancreatic islets in LGALS3 −/− mice suggest an important role for galectin-3 in the regulation of adiposity, metaflammation and type 2 diabetes.
Author	Pantic, Jelena M Lukic, Miodrag L Radosavljevic, Gordana D Pejnovic, Nada N Arsenijevic, Nebojsa N Jovanovic, Ivan P Djukic, Aleksandar Lj
Author_xml	– sequence: 1 givenname: Nada N surname: Pejnovic fullname: Pejnovic, Nada N – sequence: 2 givenname: Jelena M surname: Pantic fullname: Pantic, Jelena M – sequence: 3 givenname: Ivan P surname: Jovanovic fullname: Jovanovic, Ivan P – sequence: 4 givenname: Gordana D surname: Radosavljevic fullname: Radosavljevic, Gordana D – sequence: 5 givenname: Aleksandar Lj surname: Djukic fullname: Djukic, Aleksandar Lj – sequence: 6 givenname: Nebojsa N surname: Arsenijevic fullname: Arsenijevic, Nebojsa N – sequence: 7 givenname: Miodrag L surname: Lukic fullname: Lukic, Miodrag L email: miodrag.lukic@medf.kg.ac.rs
BackLink	https://cir.nii.ac.jp/crid/1873398392477849472$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/24052904$$D View this record in MEDLINE/PubMed
BookMark	eNptkUtrHiEUhqWkNJdm0x9QXHRRApPo6KizKZSQpIVAF8miOzlRJ7U4-lWdlPz7OvmS0JYIXsDnPC-cs492YooOoXeUHHMq6AlYvznuuVL0Fdrrqeg7NsrvO89vPuyiw1J-krYEGQSnb9Buz8nQj4TvoasLCM5UHzuGfcGAs7tdAtSUcZrw7CpMAeYZqk8R-4jXuFQcrr6UxWGIFm8gmuwaYZohuFreotcThOIOH-8DdH1-dn36pbv8dvH19PNlZzgfa0elmAZrLMBgRkFHY6BXaiSWWWoU4db2EpQAB8pKyqnhSjg3gJA3g6WCHaBPW-1muZmdNS7WDEFvsp8h3-sEXv_7E_0PfZvuNJOSS8Kb4OOjIKdfiytVz74YFwJEl5aiKWdcrnto6Pu_s55DnhrZALIFTE6lZDdp4-tD11q0D5oSvY5Lr_3TD-NqJUf_lTxZX4Q_bOHofVOvJ1WSsVGxsedSKj5y2Tds2GI-TinP8DvlYHWF-5DylNugfNHsBf0fswS0Hw
CitedBy_id	crossref_primary_10_1161_JAHA_115_002347 crossref_primary_10_1155_2017_8162421 crossref_primary_10_1016_j_dci_2020_103721 crossref_primary_10_1515_sjecr_2016_0011 crossref_primary_10_1080_13880209_2021_1953541 crossref_primary_10_3748_wjg_v22_i44_9706 crossref_primary_10_1002_oby_24363 crossref_primary_10_1007_s10735_020_09898_1 crossref_primary_10_3390_nu9040385 crossref_primary_10_1093_femspd_ftx046 crossref_primary_10_1016_j_cyto_2014_06_016 crossref_primary_10_2478_sjecr_2022_0008 crossref_primary_10_1016_j_biopha_2020_111066 crossref_primary_10_1186_s12902_020_00617_1 crossref_primary_10_1002_ejhf_1771 crossref_primary_10_1016_j_jff_2016_08_052 crossref_primary_10_1074_jbc_M116_715748 crossref_primary_10_1016_j_ijbiomac_2019_09_118
Cites_doi	10.1096/fj.09-151340 10.1038/nm1166 10.1002/hep.25542 10.4049/jimmunol.181.4.2781 10.1093/glycob/cwt006 10.1002/path.2065 10.1371/journal.pone.0057915 10.2337/db08-1261 10.4049/jimmunol.180.4.2650 10.1073/pnas.1100255108 10.1016/j.febslet.2012.02.045 10.1161/ATVBAHA.109.198614 10.1161/ATVBAHA.109.186791 10.1172/JCI28898 10.1172/JCI200319246 10.1172/JCI64941 10.1007/s10585-011-9383-y 10.1038/nm.2627 10.1038/nature01137 10.1038/nm.1964 10.1172/JCI29881 10.2337/db07-1403 10.1096/fj.01-0006com 10.1016/j.jhep.2010.09.020 10.1126/science.1184003 10.1016/S0002-9440(10)64975-9 10.1016/j.bbrc.2006.03.105 10.1152/physiolgenomics.00035.2011 10.2337/db12-0222 10.1073/pnas.0903497106 10.1016/j.bbrc.2006.05.170 10.1097/MED.0b013e32833bf6dc 10.4049/jimmunol.1201851 10.1002/oby.20016 10.4049/jimmunol.182.2.1167 10.1146/annurev-immunol-031210-101322 10.1172/JCI57132 10.1038/nm.2002 10.1038/nri2925 10.1016/j.clim.2008.08.024 10.1038/nm.2279 10.1038/oby.2010.1 10.1073/pnas.0908771107 10.1172/JCI62308 10.1038/39335 10.1111/j.1749-6632.2009.05131.x
ContentType	Journal Article
Copyright	Copyright © 2013 Landes Bioscience 2013
Copyright_xml	– notice: Copyright © 2013 Landes Bioscience 2013
DBID	0YH RYH AAYXX CITATION NPM 7X8 5PM
DOI	10.4161/adip.24881
DatabaseName	Taylor & Francis Open Access CiNii Complete CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology
EISSN	2162-397X
EndPage	271
ExternalDocumentID	PMC3774704 24052904 10_4161_adip_24881 10924881
Genre	Commentary Journal Article
GroupedDBID	0YH 53G ABCCY ACGFS ADBBV ADCVX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD BAWUL BLEHA CCCUG DEAQA DIK EBS ECGQY EMOBN EUPTU GROUPED_DOAJ GTTXZ GX1 H13 HYE KTTOD M4Z O9- OK1 OVD QZIEQ RPM TDBHL TEORI TFL TFW RYH AAYXX CITATION NPM 7X8 5PM
ID	FETCH-LOGICAL-c449t-176f5dcdaa5c9619cca28890d3d1c804dd27a86aea8d7141c486ee5a67b5d163
IEDL.DBID	0YH
ISICitedReferencesCount	18
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000218788100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2162-3945
IngestDate	Tue Nov 04 01:59:43 EST 2025 Sun Nov 09 11:30:04 EST 2025 Thu Jan 02 22:14:23 EST 2025 Sat Nov 29 02:32:03 EST 2025 Tue Nov 18 22:12:02 EST 2025 Mon Nov 10 09:17:07 EST 2025 Mon Oct 20 23:39:38 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	type 2 diabetes NFκB inflammation IL-1β NLRP3 inflammasome galectin-3 insulin resistance obesity
Language	English
License	open-access: http://creativecommons.org/licenses/by-nc/3.0/: This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c449t-176f5dcdaa5c9619cca28890d3d1c804dd27a86aea8d7141c486ee5a67b5d163
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-1169-2378 0000-0003-4123-2177
OpenAccessLink	https://www.tandfonline.com/doi/abs/10.4161/adip.24881
PMID	24052904
PQID	1434743475
PQPubID	23479
PageCount	6
ParticipantIDs	proquest_miscellaneous_1434743475 crossref_primary_10_4161_adip_24881 informaworld_taylorfrancis_310_4161_adip_24881 crossref_citationtrail_10_4161_adip_24881 pubmed_primary_24052904 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3774704 nii_cinii_1873398392477849472
PublicationCentury	2000
PublicationDate	2013-10-22
PublicationDateYYYYMMDD	2013-10-22
PublicationDate_xml	– month: 10 year: 2013 text: 2013-10-22 day: 22
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Adipocyte
PublicationTitleAlternate	Adipocyte
PublicationYear	2013
Publisher	Taylor & Francis Informa UK Limited Landes Bioscience
Publisher_xml	– name: Taylor & Francis – name: Informa UK Limited – name: Landes Bioscience
References	R41 R40 R21 R43 R20 R42 R23 R45 R44 R25 R24 R46 R27 R26 R29 R28 R1 R2 R3 R4 R5 R6 R7 R8 R9 Dinarello CA (R22) 2010; 17 R30 R10 R32 R31 R12 R34 R11 R33 R14 R36 R13 R35 R16 R38 R15 R37 R18 R17 R39 R19 17053832 - J Clin Invest. 2006 Nov;116(11):3015-25 23257358 - J Clin Invest. 2013 Jan;123(1):261-71 17200717 - J Clin Invest. 2007 Jan;117(1):175-84 21633179 - J Clin Invest. 2011 Jun;121(6):2111-7 19633658 - Nat Med. 2009 Aug;15(8):914-20 15685173 - Nat Med. 2005 Feb;11(2):183-90 16600178 - Biochem Biophys Res Commun. 2006 May 26;344(1):406-15 21876127 - Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15324-9 20445103 - Proc Natl Acad Sci U S A. 2010 May 25;107(21):9765-70 20111012 - Obesity (Silver Spring). 2010 Oct;18(10):1918-25 18305141 - Diabetes. 2008 Jun;57(6):1470-81 19359660 - Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):831-6 22213244 - Hepatology. 2012 Jun;55(6):1954-64 12447443 - Nature. 2002 Nov 21;420(6913):333-6 23401338 - Obesity (Silver Spring). 2013 Feb;21(2):310-9 9335502 - Nature. 1997 Oct 9;389(6651):610-4 20075245 - Science. 2010 Jan 15;327(5963):296-300 21217695 - Nat Med. 2011 Feb;17 (2):179-88 19690064 - Diabetes. 2009 Nov;58(11):2525-35 23349493 - Diabetes. 2013 Jun;62(6):1932-44 19706535 - Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14496-501 20371626 - FASEB J. 2010 Aug;24(8):2596-611 14679176 - J Clin Invest. 2003 Dec;112(12):1796-808 16781673 - Biochem Biophys Res Commun. 2006 Aug 4;346(3):739-45 10702423 - Am J Pathol. 2000 Mar;156(3):1073-83 18684969 - J Immunol. 2008 Aug 15;181(4):2781-9 18250477 - J Immunol. 2008 Feb 15;180(4):2650-8 22569257 - FEBS Lett. 2012 Apr 5;586(7):1022-6 21145823 - J Hepatol. 2011 May;54(5):975-83 11689472 - FASEB J. 2001 Nov;15(13):2471-9 21219177 - Annu Rev Immunol. 2011;29:415-45 23426722 - Glycobiology. 2013 Jun;23(6):654-63 23221344 - J Clin Invest. 2013 Jan;123(1):215-23 18845486 - Clin Immunol. 2009 Jan;130(1):83-8 22395709 - Nat Med. 2012 Mar 06;18(3):363-74 21442355 - Clin Exp Metastasis. 2011 Jun;28(5):451-62 23175698 - J Immunol. 2012 Dec 15;189(12):5934-41 20146714 - Ann N Y Acad Sci. 2010 Jan;1183:158-82 21791638 - Physiol Genomics. 2011 Oct 20;43(20):1144-52 17029217 - J Pathol. 2006 Dec;210(4):469-77 20588114 - Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):314-21 19910631 - Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):193-9 21233852 - Nat Rev Immunol. 2011 Feb;11(2):98-107 19633656 - Nat Med. 2009 Aug;15(8):930-9 23451284 - PLoS One. 2013;8(2):e57915 19124760 - J Immunol. 2009 Jan 15;182(2):1167-73
References_xml	– ident: R19 doi: 10.1096/fj.09-151340 – ident: R16 doi: 10.1038/nm1166 – ident: R28 doi: 10.1002/hep.25542 – ident: R30 doi: 10.4049/jimmunol.181.4.2781 – ident: R46 doi: 10.1093/glycob/cwt006 – ident: R36 doi: 10.1002/path.2065 – ident: R44 doi: 10.1371/journal.pone.0057915 – ident: R12 doi: 10.2337/db08-1261 – ident: R40 doi: 10.4049/jimmunol.180.4.2650 – ident: R18 doi: 10.1073/pnas.1100255108 – ident: R42 doi: 10.1016/j.febslet.2012.02.045 – ident: R5 doi: 10.1161/ATVBAHA.109.198614 – ident: R32 doi: 10.1161/ATVBAHA.109.186791 – ident: R17 doi: 10.1172/JCI28898 – ident: R6 doi: 10.1172/JCI200319246 – ident: R13 doi: 10.1172/JCI64941 – ident: R29 doi: 10.1007/s10585-011-9383-y – ident: R1 doi: 10.1038/nm.2627 – ident: R20 doi: 10.1038/nature01137 – ident: R8 doi: 10.1038/nm.1964 – ident: R10 doi: 10.1172/JCI29881 – ident: R43 doi: 10.2337/db07-1403 – ident: R31 doi: 10.1096/fj.01-0006com – ident: R35 doi: 10.1016/j.jhep.2010.09.020 – ident: R15 doi: 10.1126/science.1184003 – ident: R24 doi: 10.1016/S0002-9440(10)64975-9 – ident: R33 doi: 10.1016/j.bbrc.2006.03.105 – ident: R34 doi: 10.1152/physiolgenomics.00035.2011 – ident: R38 doi: 10.2337/db12-0222 – ident: R39 doi: 10.1073/pnas.0903497106 – ident: R14 doi: 10.1016/j.bbrc.2006.05.170 – volume: 17 start-page: 314 year: 2010 ident: R22 publication-title: Curr Opin Endocrinol Diabetes Obes doi: 10.1097/MED.0b013e32833bf6dc – ident: R25 doi: 10.4049/jimmunol.1201851 – ident: R37 doi: 10.1002/oby.20016 – ident: R26 doi: 10.4049/jimmunol.182.2.1167 – ident: R2 doi: 10.1146/annurev-immunol-031210-101322 – ident: R3 doi: 10.1172/JCI57132 – ident: R7 doi: 10.1038/nm.2002 – ident: R21 doi: 10.1038/nri2925 – ident: R27 doi: 10.1016/j.clim.2008.08.024 – ident: R41 doi: 10.1038/nm.2279 – ident: R4 doi: 10.1038/oby.2010.1 – ident: R11 doi: 10.1073/pnas.0908771107 – ident: R45 doi: 10.1172/JCI62308 – ident: R9 doi: 10.1038/39335 – ident: R23 doi: 10.1111/j.1749-6632.2009.05131.x – reference: 22213244 - Hepatology. 2012 Jun;55(6):1954-64 – reference: 17053832 - J Clin Invest. 2006 Nov;116(11):3015-25 – reference: 20371626 - FASEB J. 2010 Aug;24(8):2596-611 – reference: 21217695 - Nat Med. 2011 Feb;17 (2):179-88 – reference: 23257358 - J Clin Invest. 2013 Jan;123(1):261-71 – reference: 19706535 - Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14496-501 – reference: 21219177 - Annu Rev Immunol. 2011;29:415-45 – reference: 19359660 - Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):831-6 – reference: 15685173 - Nat Med. 2005 Feb;11(2):183-90 – reference: 21876127 - Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15324-9 – reference: 11689472 - FASEB J. 2001 Nov;15(13):2471-9 – reference: 22569257 - FEBS Lett. 2012 Apr 5;586(7):1022-6 – reference: 21442355 - Clin Exp Metastasis. 2011 Jun;28(5):451-62 – reference: 16600178 - Biochem Biophys Res Commun. 2006 May 26;344(1):406-15 – reference: 16781673 - Biochem Biophys Res Commun. 2006 Aug 4;346(3):739-45 – reference: 21233852 - Nat Rev Immunol. 2011 Feb;11(2):98-107 – reference: 9335502 - Nature. 1997 Oct 9;389(6651):610-4 – reference: 12447443 - Nature. 2002 Nov 21;420(6913):333-6 – reference: 14679176 - J Clin Invest. 2003 Dec;112(12):1796-808 – reference: 19124760 - J Immunol. 2009 Jan 15;182(2):1167-73 – reference: 19633658 - Nat Med. 2009 Aug;15(8):914-20 – reference: 18305141 - Diabetes. 2008 Jun;57(6):1470-81 – reference: 17029217 - J Pathol. 2006 Dec;210(4):469-77 – reference: 10702423 - Am J Pathol. 2000 Mar;156(3):1073-83 – reference: 21633179 - J Clin Invest. 2011 Jun;121(6):2111-7 – reference: 21145823 - J Hepatol. 2011 May;54(5):975-83 – reference: 20075245 - Science. 2010 Jan 15;327(5963):296-300 – reference: 23175698 - J Immunol. 2012 Dec 15;189(12):5934-41 – reference: 20588114 - Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):314-21 – reference: 20146714 - Ann N Y Acad Sci. 2010 Jan;1183:158-82 – reference: 20445103 - Proc Natl Acad Sci U S A. 2010 May 25;107(21):9765-70 – reference: 23401338 - Obesity (Silver Spring). 2013 Feb;21(2):310-9 – reference: 23349493 - Diabetes. 2013 Jun;62(6):1932-44 – reference: 23221344 - J Clin Invest. 2013 Jan;123(1):215-23 – reference: 17200717 - J Clin Invest. 2007 Jan;117(1):175-84 – reference: 19910631 - Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):193-9 – reference: 18845486 - Clin Immunol. 2009 Jan;130(1):83-8 – reference: 21791638 - Physiol Genomics. 2011 Oct 20;43(20):1144-52 – reference: 18684969 - J Immunol. 2008 Aug 15;181(4):2781-9 – reference: 23426722 - Glycobiology. 2013 Jun;23(6):654-63 – reference: 19633656 - Nat Med. 2009 Aug;15(8):930-9 – reference: 20111012 - Obesity (Silver Spring). 2010 Oct;18(10):1918-25 – reference: 22395709 - Nat Med. 2012 Mar 06;18(3):363-74 – reference: 18250477 - J Immunol. 2008 Feb 15;180(4):2650-8 – reference: 19690064 - Diabetes. 2009 Nov;58(11):2525-35 – reference: 23451284 - PLoS One. 2013;8(2):e57915
SSID	ssj0000605641 ssib051604300
Score	1.9716188
Snippet	The cells of the innate and adaptive immune systems have been implicated in the development of obesity-induced metaflammation and metabolic disorders including...
SourceID	pubmedcentral proquest pubmed crossref nii informaworld
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	266
SubjectTerms	Commentary galectin-3 IL-1β inflammation insulin resistance NFκB NLRP3 inflammasome obesity type 2 diabetes
Title	Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets
URI	https://www.tandfonline.com/doi/abs/10.4161/adip.24881 https://cir.nii.ac.jp/crid/1873398392477849472 https://www.ncbi.nlm.nih.gov/pubmed/24052904 https://www.proquest.com/docview/1434743475 https://pubmed.ncbi.nlm.nih.gov/PMC3774704
Volume	2
WOSCitedRecordID	wos000218788100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2162-397X dateEnd: 99991231 omitProxy: false ssIdentifier: ssib051604300 issn: 2162-3945 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 2162-397X dateEnd: 20171002 omitProxy: false ssIdentifier: ssj0000605641 issn: 2162-3945 databaseCode: TFW dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2162-397X dateEnd: 20140131 omitProxy: false ssIdentifier: ssj0000605641 issn: 2162-3945 databaseCode: 0YH dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2162-397X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605641 issn: 2162-3945 databaseCode: 0YH dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqlgMXoJTHlhYZgZA4pDjOJLaPVcXSA6qQWInlFDm2IyJ1k2p3i8S_74y9u-pWe4FDfIkdP2ZsfzOxv2HsQwGurQQ0WdW2PoPGQGa88plqiHxTEYNZvCj8TV1d6enUfN9j1fouDB2rJBu6TUQRca2myW2bGIGE4Phn67ubM4mah1bPgUR7hI5yiV-XG9-KQIxexaCVMq9kVhgoEzPpg-Jbe9EWUynuNH3X7UKdDw9P3tuNxk__tx_P2JMV_uTnSWEO2V7on7Oj8x5t79lf_pHHE6HR1X7Efny15NTv-qzg3YJbPk-B64c5H1o-CxT5187S3Ufe9ZxqGhaBL6MwObaL41qTYKnDL6CKLF6wyfjL5OIyWwVhyByAWRKBZFt6560tnUFrCyUutTbCFz53WoD3Ulld2WC1VznkDnQVQmkr1ZQewd5Ltt8PfXjNuLAOsUBwwQkNJeS6gQKUy4UNpgxajtintTRqtyIopzgZ1zUaKjRgNXWjjgM2Yu83eW8SLcfOXGf3hVovoxOkTRFL6mJXgVMUO9ZOaa5VURgCkKCUBgMKm_hurRA1TkP6t2L7MNwu0ILCvtBTjtirpCCbhiFoKqURMGJqS3U2GYjie_tN3_2OVN8FonMl4PhfO_KGPZYUtwM3WSlP2P5yfhtO2SP3BzVg_jbOFkzVVGM6Gf-8A58FGjg
linkProvider	Taylor & Francis
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQQYJLeZTHAgUjEBKHlDzGsX2sEEsRywqJlegtcmxHjcQm1WZbiX_PjJ2uutVe4JBcYie2Z2x_Mxl_w9i7AmxTplAnZdO4BGoNiXbSJbIm8k1JDGbhoPBMzufq9FT_GF0XwxhWSTZ0E4kiwlpNk5uc0TTDCY9_NK49P8pR9dDsuS1wg6VYvsX018a5kiJIL0PWyjwr86TQICI16Y3qW5vRFlUpbjVd2-6CnTejJ69tR9P7_92RB2x_RKD8OKrMQ3bLd4_YwXGH1vfyD3_PQ0xocLYfsJ9fDLn12y4peDtww1cxdX2_4n3Dl55y_5plPP3I247Tl_rB83UQJ8eGcVxtIjC1-AZUkuExW0w_Lz6dJGMahsQC6DVRSDbCWWeMsBrtLZR5rpROXeEyq1JwLpdGlcYb5WQGmQVVei9MKWvhEO49YXtd3_lnjKfGIhrw1ttUgYBM1VCAtFlqvBZe5RP24UoclR0pyilTxu8KTRUasIq6UYUBm7C3m7LnkZhjZ6mj61Kt1sEN0sScJVWxq8Ihyh2_TvdMyaLQBCFBSgUaJDbxzZVGVDgR6e-K6Xx_MaANhX2hS0zY06ghm4YhbBK5TmHC5JbubAoQyff2k649C2TfBeJzmcLzf-3Ia3b3ZPF9Vs2-zr-9YPdyyuIRYhBfsr316sIfsjv2ErVh9SpMnb94_xxl
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZWC0JceC2PAgtGICQOWRJnHNvHFVBArKqVqMTeIsd2RCTqVG0XiX_PjNNW21UvcEgusROPZ8b-xrG_YexNCa6tcmiyqm19Bo2BzHjlM9UQ-aYiBrN0UPhMTSb64sKcH7BqcxaGtlVSDN0ORBFprCbnnvuWHJzg-Hvru_mJQMvDqOdGYsRCO56Of2zXVnLE6FVKWimKSmSlATkwk16rvjMX7TCV4kwTu24f6ry-efLKbDS--79y3GN31viTnw4Gc58dhPiAHZ1GjL1nf_hbnnaEpqX2I_b9s6VF_S5mJe-W3PLFkLi-X_C-5bNAmX_tbDj7yLvI6Uv9MvBVUibHdnEcawZY6vANaCLLh2w6_jT98CVbJ2HIHIBZEYFkK73z1kpnMNpCjQutTe5LXzidg_dCWV3ZYLVXBRQOdBWCtJVqpEew94gdxj6GJ4zn1iEWCC64XIOEQjdQgnJFboORQYsRe7fRRu3WBOWUJ-NXjYEKdVhNYtSpw0bs9bbsfKDl2Fvq5KpS61VaBGmHjCV1ua_CMaodv073QquyNAQgQSkNBhQ28dXGIGp0Q_q3YmPoL5cYQaEsdMkRezwYyLZhCJqkMDmMmNoxnW0BovjefRK7n4nqu0R0rnJ4-q-CvGS3zj-O67Ovk2_P2G1BKTxwvhXiOTtcLS7DMbvpfqMxLF4kx_kL9F0bDA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Galectin-3+is+a+regulator+of+metaflammation+in+adipose+tissue+and+pancreatic+islets&rft.jtitle=Adipocyte&rft.au=Pejnovic%2C+Nada+N&rft.au=Pantic%2C+Jelena+M&rft.au=Jovanovic%2C+Ivan+P&rft.au=Radosavljevic%2C+Gordana+D&rft.date=2013-10-22&rft.issn=2162-3945&rft.eissn=2162-397X&rft.volume=2&rft.issue=4&rft.spage=266&rft.epage=271&rft_id=info:doi/10.4161%2Fadip.24881&rft.externalDBID=n%2Fa&rft.externalDocID=10_4161_adip_24881
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-3945&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-3945&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-3945&client=summon